ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis. Shares rise.